Key result
Skin advanced glycation end products linked to higher aPWV in type 1 diabetes.
Why the study?
Are advanced glycation end products associated with arterial stiffness in patients with type 1 diabetes without clinical cardiovascular events?
Population
136 subjects: 68 patients with type 1 diabetes without clinical cardiovascular events and 68 age- and…
Design
Case-control
Authors
Loading...
Supports AGE skin autofluorescence as vascular marker in T1D; hypothesis-generating, requires prospective validation before clinical use.
Observational (n=136)
Are advanced glycation end products associated with arterial stiffness in patients with type 1 diabetes without clinical cardiovascular events?
Effect estimate: β=0.380
p-value: p=<0.001
Skin accumulation of autofluorescent advanced glycation end products is independently associated with arterial stiffness in patients with type 1 diabetes, suggesting its potential as a marker for vascular risk.
Llauradó et al. (2014) conducted an observational in Type 1 diabetes without clinical cardiovascular events (n=136). Advanced glycation end products (skin autofluorescence) was evaluated on Aortic pulse wave velocity (aPWV) (β=0.380, p=<0.001). Skin accumulation of autofluorescent advanced glycation end products was independently associated with arterial stiffness (aPWV) in subjects with type 1 diabetes (β=0.380; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: